Gossamer Bio (GOSS) Total Current Liabilities (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Total Current Liabilities of $56.5 million for Q1 2026, up 17.18% year-over-year from $48.2 million in Q1 2025, and down 10.92% quarter-over-quarter from $63.4 million in Q4 2025.
Gossamer Bio (GOSS) Total Current Liabilities (2018 - 2026) Analysis & Trends
Gossamer Bio's Total Current Liabilities history runs 9 years deep, the most recent figure standing at $56.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 17.18% year-over-year to $56.5 million; the TTM figure through Mar 2026 stood at $56.5 million (up 17.18% YoY), while the FY2025 annual figure was $63.4 million, up 40.94% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $56.5 million, down from $63.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $63.4 million in Q4 2025, with the low at $34.6 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $48.2 million (2025), against an average of $48.0 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 48.12% in 2022, then fell 19.62% in 2023.
- Gossamer Bio's Total Current Liabilities stood at $49.2 million in 2022, then gained by 4.81% to $51.6 million in 2023, then declined by 12.77% to $45.0 million in 2024, then surged by 40.94% to $63.4 million in 2025, then decreased by 10.92% to $56.5 million in 2026.
- Business Quant data shows GOSS's Total Current Liabilities at $56.5 million in Q1 2026, $63.4 million in Q4 2025, and $62.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 137.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.78 Mn |
| Mar 31, 2026 | 56.51 Mn |
| Dec 31, 2025 | 63.44 Mn |
| Sep 30, 2025 | 62.12 Mn |
| Jun 30, 2025 | 53.59 Mn |
| Mar 31, 2025 | 48.22 Mn |
| Dec 31, 2024 | 45.01 Mn |
| Sep 30, 2024 | 51.09 Mn |
| Jun 30, 2024 | 45.19 Mn |
| Mar 31, 2024 | 35.82 Mn |
| Dec 31, 2023 | 51.60 Mn |
| Sep 30, 2023 | 42.32 Mn |
| Jun 30, 2023 | 40.14 Mn |
| Mar 31, 2023 | 40.57 Mn |
| Dec 31, 2022 | 49.23 Mn |
| Sep 30, 2022 | 52.65 Mn |
| Jun 30, 2022 | 44.41 Mn |
| Mar 31, 2022 | 34.57 Mn |
| Dec 31, 2021 | 39.86 Mn |
| Sep 30, 2021 | 35.90 Mn |